BiochemProbe — Life Science Research Reagents

WM382 free base · Synonyms: WM-382 · WM 382

WM382 is an orally active and potent dual plasmepsin IX/X inhibitor.

For research use only. Not for human or veterinary use.

Target Parasite
Research area Infection
Purity >98% Stock Inquire

WM382 structure

CAS No.: 2606990-92-3

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
100 mg USD 4,800.00 BP-02241-100mg In stock Get quote
250 mg Inquire BP-02241-250mg In stock Inquire

Need another size or custom synthesis? Request a quote.

Description

WM382 is an orally active and potent dual plasmepsin IX/X (PMIX/X) inhibitor with IC50 values of 1.4 nM and 0.03 nM, respectively. WM382 has robust in vivo efficacy at multiple stages of the malaria parasite life cycle and an excellent resistance profile.

Biological activity

In Vitro WM382 shows moderate cytotoxicity against HepG2 cells (IC50=24.8 μM), and inhibits Plasmodium falciparum and P. vivax with an IC50 value of 0.6 nM (P. falciparum). WM382 selectively binds PMV and PMX with Ki values of 13.4 μM and 0.035 nM, respectively. WM382 (1 nM and 100 nM) reminds the time to patent blood infection following injection of 65 h in P. berghei-infected HepG2 in vitro cultures. In Vivo WM382 (20 mg/kg twice daily or 1-30 mg/kg once daily; p.o.; for 4 d) can clear mouse models of P. berghei and P. falciparum parasites. WM382 is also efficacious against P. falciparum asexual infection in humanized mice and prevents transmission to mosquitoes.

Identifiers

SMILES
O=C(C1=CC([C@H](N(C(NC(CC)(CC)C2)=N)C2=O)CCO3)=C3C=C1)N[C@H]4CC(C)(C)OC5=C4C=CC=C5
InChIKey
ZSZSSSHEMYULPX-FCHUYYIVSA-N

Specifications

MW (average)
504.6205
Formula
C29H36N4O4
CAS No.
2606990-92-3
Physical state
Solid
Color
White to off-white
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder -20℃ 3 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

In vitro
DMSO 5 mg/mL

References

[1]. Manuel de LR, et al. The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria. ACS Med Chem Lett. 2022 Oct 12.
[2]. Hodder AN, et al. Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax. Structure. 2022 Jul 7;30(7):947-961.e6.
[3]. Favuzza P, et al. Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle. Cell Host Microbe. 2020 Apr 8;27(4):642-658.e12.

Same target

Search Parasite

Same research area

Search Infection